Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study

BACKGROUND: As the first gene therapy for spinal muscular atrophy (SMA), nusinersen is supposed to be administrated via intrathecal injection regularly for a lifetime. However, for SMA patients with severe spinal deformities, bony fusion following posterior spinal instrumentation sets great obstacle...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Feng, Erwei, Jiao, Yang, Zhao, Junduo, Chen, Xin, Zhang, Haozhi, Liang, Jinqian, Li, Zheng, Cui, Xulei, Chen, Weiyun, Shen, Jianxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685557/
https://www.ncbi.nlm.nih.gov/pubmed/38031122
http://dx.doi.org/10.1186/s13023-023-02972-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685557/
https://www.ncbi.nlm.nih.gov/pubmed/38031122
http://dx.doi.org/10.1186/s13023-023-02972-3

Ejemplares similares